WO2000066142A2 - Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain - Google Patents
Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain Download PDFInfo
- Publication number
- WO2000066142A2 WO2000066142A2 PCT/US2000/011652 US0011652W WO0066142A2 WO 2000066142 A2 WO2000066142 A2 WO 2000066142A2 US 0011652 W US0011652 W US 0011652W WO 0066142 A2 WO0066142 A2 WO 0066142A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- administration
- ischemic
- pmol
- biologically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00928616A EP1187628B1 (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
IL14582900A IL145829A0 (en) | 1999-04-30 | 2000-05-01 | Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1 |
DE60035987T DE60035987T2 (en) | 1999-04-30 | 2000-05-01 | METABOLIC INTERVENTION WITH GLP-1 OR ITS BIOLOGICALLY ACTIVE ANALOGS TO IMPROVE THE FUNCTION OF THE ISCHEMIC AND RECHAPTERED BRAIN |
CA2368772A CA2368772C (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
MXPA01010937A MXPA01010937A (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain. |
JP2000615026A JP2002543145A (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention using GLP-1 or a biologically active analog thereof for improving brain function in ischemia and reperfusion injury |
AU46825/00A AU774084B2 (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
NZ514609A NZ514609A (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
NO20015298A NO20015298L (en) | 1999-04-30 | 2001-10-29 | Metabolic intervention with GLP-1 or its biologically active analogs to improve the function of the ischemic and reperfused brain |
AU2004212547A AU2004212547B2 (en) | 1999-04-30 | 2004-09-15 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/303,016 | 1999-04-30 | ||
US09/303,016 US6429197B1 (en) | 1998-10-08 | 1999-04-30 | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000066142A2 true WO2000066142A2 (en) | 2000-11-09 |
WO2000066142A3 WO2000066142A3 (en) | 2002-01-24 |
Family
ID=23170209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/011652 WO2000066142A2 (en) | 1999-04-30 | 2000-05-01 | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Country Status (14)
Country | Link |
---|---|
US (2) | US6429197B1 (en) |
EP (1) | EP1187628B1 (en) |
JP (1) | JP2002543145A (en) |
CN (1) | CN1376072A (en) |
AT (1) | ATE369873T1 (en) |
AU (2) | AU774084B2 (en) |
CA (1) | CA2368772C (en) |
DE (1) | DE60035987T2 (en) |
ES (1) | ES2290029T3 (en) |
IL (1) | IL145829A0 (en) |
MX (1) | MXPA01010937A (en) |
NO (1) | NO20015298L (en) |
NZ (1) | NZ514609A (en) |
WO (1) | WO2000066142A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001089554A3 (en) * | 2000-05-19 | 2002-06-13 | Bionebraska Inc | Treatment of acute coronary syndrome with glp-1 |
JP2002293799A (en) * | 2001-03-29 | 2002-10-09 | Itoham Foods Inc | New peptide and enterokinesis inhibitor containing the same |
EP1411968A2 (en) * | 2001-07-31 | 2004-04-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
WO2004071393A2 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
EP2062593A2 (en) | 2000-12-01 | 2009-05-27 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive peptide |
WO2010013012A3 (en) * | 2008-08-01 | 2010-04-01 | Lund University Bioscience Ab | Hypothermia inducing polypeptides and uses thereof |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7914499B2 (en) | 2006-03-30 | 2011-03-29 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
US8070726B2 (en) | 2003-04-23 | 2011-12-06 | Valeritas, Inc. | Hydraulically actuated pump for long duration medicament administration |
WO2014010586A1 (en) | 2012-07-10 | 2014-01-16 | 武田薬品工業株式会社 | Pharmaceutical preparation for injection |
CN103566354A (en) * | 2012-07-25 | 2014-02-12 | 江苏豪森药业股份有限公司 | Pharmaceutical composition containing derivatives of GLP-1 analogue or medicinal salts thereof |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
WO2017192449A1 (en) * | 2016-05-06 | 2017-11-09 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849708B1 (en) * | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US7138486B2 (en) * | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US20060160740A1 (en) * | 1999-10-21 | 2006-07-20 | Suad Efendic | Use of GLP-1 or analogs in treatment of stroke |
EA008837B1 (en) * | 2000-06-16 | 2007-08-31 | Эли Лилли Энд Компани | Glucagon-like peptide-1 analogs and use thereof |
EP1701731A4 (en) * | 2003-12-12 | 2009-08-05 | Einstein Coll Med | Glp-1 (9-36) methods and compositions |
US20080194483A1 (en) * | 2003-12-12 | 2008-08-14 | Brownlee Michael A | GLP-1 (9-36) methods and compositions |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
EP2459251B1 (en) | 2009-07-30 | 2014-03-12 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN101706297B (en) * | 2009-08-10 | 2012-10-17 | 浙江鼎立实业有限公司 | Digital display micropressure and micro-flow comprehensive test bed |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
ES2688367T3 (en) | 2012-12-21 | 2018-11-02 | Sanofi | Derivatives of exendin-4 as dual agonists of GLP1 / GIP or trigonal of GLP1 / GIP / glucagon |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
WO1994015925A1 (en) * | 1993-01-14 | 1994-07-21 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
WO1998043658A1 (en) * | 1997-03-31 | 1998-10-08 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO2000016797A2 (en) * | 1998-09-24 | 2000-03-30 | Eli Lilly And Company | Use of glp-1 or analogs in treatment of stroke |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4976959A (en) * | 1986-05-12 | 1990-12-11 | Burroughs Wellcome Co. | T-PA and SOD in limiting tissue damage |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5373016A (en) | 1993-05-28 | 1994-12-13 | Zeneca, Inc. | Protection of isothiazolinone biocides from free radicals |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
ES2247676T3 (en) | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | USE OF THE EXENDINAS AND THE AGONISTS OF THE SAME FOR THE REDUCTION OF FOOD INGESTION. |
US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
CA2395165C (en) | 2000-10-20 | 2012-05-22 | Mario Ehlers | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
-
1999
- 1999-04-30 US US09/303,016 patent/US6429197B1/en not_active Ceased
-
2000
- 2000-05-01 JP JP2000615026A patent/JP2002543145A/en active Pending
- 2000-05-01 NZ NZ514609A patent/NZ514609A/en not_active IP Right Cessation
- 2000-05-01 DE DE60035987T patent/DE60035987T2/en not_active Expired - Lifetime
- 2000-05-01 MX MXPA01010937A patent/MXPA01010937A/en active IP Right Grant
- 2000-05-01 WO PCT/US2000/011652 patent/WO2000066142A2/en active Search and Examination
- 2000-05-01 AT AT00928616T patent/ATE369873T1/en not_active IP Right Cessation
- 2000-05-01 EP EP00928616A patent/EP1187628B1/en not_active Expired - Lifetime
- 2000-05-01 ES ES00928616T patent/ES2290029T3/en not_active Expired - Lifetime
- 2000-05-01 CN CN00806935A patent/CN1376072A/en active Pending
- 2000-05-01 AU AU46825/00A patent/AU774084B2/en not_active Ceased
- 2000-05-01 IL IL14582900A patent/IL145829A0/en not_active IP Right Cessation
- 2000-05-01 CA CA2368772A patent/CA2368772C/en not_active Expired - Fee Related
-
2001
- 2001-10-29 NO NO20015298A patent/NO20015298L/en not_active Application Discontinuation
-
2004
- 2004-08-06 US US10/913,309 patent/USRE41288E1/en not_active Expired - Lifetime
- 2004-09-15 AU AU2004212547A patent/AU2004212547B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196196A (en) * | 1978-06-19 | 1980-04-01 | Tiholiz Ivan C | Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states |
WO1994015925A1 (en) * | 1993-01-14 | 1994-07-21 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
WO1998043658A1 (en) * | 1997-03-31 | 1998-10-08 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO2000016797A2 (en) * | 1998-09-24 | 2000-03-30 | Eli Lilly And Company | Use of glp-1 or analogs in treatment of stroke |
Non-Patent Citations (1)
Title |
---|
SCOTT J F ET AL: "Glucose and insulin therapy in acute stroke;why delay further?" QJM, vol. 91, no. 7, July 1998 (1998-07), pages 511-515, XP000960537 ISSN: 0033-5622 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056887B2 (en) | 2000-05-19 | 2006-06-06 | Amylin Pharmaceuticals, Inc. | Treatment of acute coronary syndrome with GLP-1 |
US6706689B2 (en) | 2000-05-19 | 2004-03-16 | Amylin Pharmaceuticals, Inc. | Treatment of acute coronary syndrome with GLP-1 |
WO2001089554A3 (en) * | 2000-05-19 | 2002-06-13 | Bionebraska Inc | Treatment of acute coronary syndrome with glp-1 |
US7981861B2 (en) | 2000-05-19 | 2011-07-19 | Amylin Pharmaceuticals, Inc. | Method of performing angioplasty with a GLP-1 molecule |
AU2001263230B2 (en) * | 2000-05-19 | 2005-03-10 | Amylin Pharmaceuticals, Llc | Treatment of acute coronary syndrome with glp-1 |
EP2062593A2 (en) | 2000-12-01 | 2009-05-27 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive peptide |
JP2002293799A (en) * | 2001-03-29 | 2002-10-09 | Itoham Foods Inc | New peptide and enterokinesis inhibitor containing the same |
US8278272B2 (en) | 2001-07-31 | 2012-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
AU2008202893B2 (en) * | 2001-07-31 | 2012-01-12 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 Exendin-4 peptide analogs and uses thereof |
EP1411968A4 (en) * | 2001-07-31 | 2005-06-15 | Us Gov Health & Human Serv | Glp-1 exendin-4 peptide analogs and uses thereof |
US7576050B2 (en) | 2001-07-31 | 2009-08-18 | The United States Of America As Represented By The Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
US10941187B2 (en) | 2001-07-31 | 2021-03-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
US8853160B2 (en) | 2001-07-31 | 2014-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
EP2275117A1 (en) | 2001-07-31 | 2011-01-19 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
EP1411968A2 (en) * | 2001-07-31 | 2004-04-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8252739B2 (en) | 2001-12-21 | 2012-08-28 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8071539B2 (en) | 2001-12-21 | 2011-12-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8513189B2 (en) | 2001-12-21 | 2013-08-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004071393A3 (en) * | 2003-02-13 | 2005-08-04 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
WO2004071393A2 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r) |
US9072828B2 (en) | 2003-04-23 | 2015-07-07 | Valeritas, Inc. | Hydraulically actuated pump for long duration medicament administration |
US8070726B2 (en) | 2003-04-23 | 2011-12-06 | Valeritas, Inc. | Hydraulically actuated pump for long duration medicament administration |
US11642456B2 (en) | 2003-04-23 | 2023-05-09 | Mannkind Corporation | Hydraulically actuated pump for fluid administration |
US10525194B2 (en) | 2003-04-23 | 2020-01-07 | Valeritas, Inc. | Hydraulically actuated pump for fluid administration |
US9511187B2 (en) | 2003-04-23 | 2016-12-06 | Valeritas, Inc. | Hydraulically actuated pump for fluid administration |
US9125983B2 (en) | 2003-04-23 | 2015-09-08 | Valeritas, Inc. | Hydraulically actuated pump for fluid administration |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
US7914499B2 (en) | 2006-03-30 | 2011-03-29 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
US8821443B2 (en) | 2006-03-30 | 2014-09-02 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
US8361053B2 (en) | 2006-03-30 | 2013-01-29 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
US9687599B2 (en) | 2006-03-30 | 2017-06-27 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
US10493199B2 (en) | 2006-03-30 | 2019-12-03 | Valeritas, Inc. | Multi-cartridge fluid delivery device |
WO2010013012A3 (en) * | 2008-08-01 | 2010-04-01 | Lund University Bioscience Ab | Hypothermia inducing polypeptides and uses thereof |
WO2014010586A1 (en) | 2012-07-10 | 2014-01-16 | 武田薬品工業株式会社 | Pharmaceutical preparation for injection |
CN103566354A (en) * | 2012-07-25 | 2014-02-12 | 江苏豪森药业股份有限公司 | Pharmaceutical composition containing derivatives of GLP-1 analogue or medicinal salts thereof |
WO2017192449A1 (en) * | 2016-05-06 | 2017-11-09 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
Also Published As
Publication number | Publication date |
---|---|
DE60035987D1 (en) | 2007-09-27 |
CA2368772C (en) | 2011-11-15 |
MXPA01010937A (en) | 2002-05-06 |
US6429197B1 (en) | 2002-08-06 |
NZ514609A (en) | 2004-03-26 |
DE60035987T2 (en) | 2008-05-08 |
AU2004212547A1 (en) | 2004-10-14 |
AU2004212547B2 (en) | 2008-03-20 |
ATE369873T1 (en) | 2007-09-15 |
CN1376072A (en) | 2002-10-23 |
ES2290029T3 (en) | 2008-02-16 |
EP1187628A2 (en) | 2002-03-20 |
EP1187628B1 (en) | 2007-08-15 |
USRE41288E1 (en) | 2010-04-27 |
CA2368772A1 (en) | 2000-11-09 |
JP2002543145A (en) | 2002-12-17 |
AU774084B2 (en) | 2004-06-17 |
IL145829A0 (en) | 2002-07-25 |
NO20015298L (en) | 2001-12-28 |
NO20015298D0 (en) | 2001-10-29 |
WO2000066142A3 (en) | 2002-01-24 |
AU4682500A (en) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1187628B1 (en) | Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain | |
EP1173197B2 (en) | Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue | |
US7259136B2 (en) | Compositions and methods for treating peripheral vascular disease | |
CA2395165C (en) | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide | |
US7056887B2 (en) | Treatment of acute coronary syndrome with GLP-1 | |
US20040266683A1 (en) | Prevention and treatment of cardiac arrhythmias | |
US20080194483A1 (en) | GLP-1 (9-36) methods and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00806935.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 514609 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 46825/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2000 615026 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000928616 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2368772 Country of ref document: CA Ref document number: 2368772 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/01319/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/010937 Country of ref document: MX |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000928616 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 46825/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000928616 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |